Suzhou Industrial Park

Home page > category report > Industries & Enterprises


Two companies initiates practice of Suzhou DMAHS


Date:   |   Source:       Font Size:    A   A   A

Suzhou Kintor Pharmaceuticals, Inc. (Kintor) and Tot Biopharm Co., Ltd. (Tot), two companies residing in SIP BioBay, recently signed the contract for commissioned pharmaceutical research and production, which initiated the practice of Suzhou's Drug Marketing Authorization Holder System (DMAHS).

Kintor is an enterprise of technological innovation devoted to the preliminary R&D of new anti-cancer drugs, and Tot boasts a specialized R&D and production platform for special dosage forms of anti-cancer drugs.

Kintor commissioned the R&D and production of a Category 1.1 new targeted drug to Tot, the two parties complementing each other in the division of labor to establish long-term inter-corporate ties of trust and cooperation, which will speed up drug innovation and improve drug quality.

"The cooperation between the two companies has officially kicked off the pilot work of Suzhou's DMAHS, " said Chen Jianmin, director of Suzhou Food and Drug Administration (SFDA).

SFDA will encourage enterprises' innovative R&D and the partnership between powerful companies while continuing to strengthen daily supervision, and step up the pilot work of DMAHS in a bid to lay a good foundation for building a hundred billion yuan level highland of biopharmaceutical industry in Suzhou.

China Food and Drug Administration listed out 10 provinces and cities including Jiangsu Province as the pilot province/city of DMAHS at the end of last year.

As per regulations, the owner with drug authorization is allowed to do either self production or commissioned production; the separation of marketing authorization from production will greatly accelerate the process and speed of new drug availability.


Source:Suzhou Daily,December 5, 2016